VEGFA and neoplasm: Several VEGF isoforms mediate tumor angiogenesis and VEGF/VEGF-receptor interactions have been targeted to modulate angiogenic responses [49]; the inhibitory anti-VEGF antibody Avastin was the first angiogenesis inhibitor to enter the market in 2004.